相关实验视频

Updated: Jul 10, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

SBRT与Y90:HCC治疗结果和成本

Mark F deBettencourt¹, Yirong Liu², Scott J Cotler¹

¹Loyola University Medical Center, Maywood.

American journal of clinical oncology

|November 20, 2023

概括

立体体辐射疗法 (SBRT) 和-90 (Y90) 在肝癌中显示出类似的生存结果. 与Y90相比,SBRT的成本明显低于Y90,这突出了HCC治疗的成本效益.

科学领域:

肝胆道恶性瘤肝胆道恶性瘤
干预性瘤学干预性瘤学
辐射瘤学辐射瘤学

背景情况:

肝细胞癌 (HCC) 是一种主要的肝癌.
立体体辐射疗法 (SBRT) 和-90 (Y90) 放射栓塞是局部HCC的废除疗法.
对SBRT与Y90的直接比较结果和成本数据是有限的.

研究的目的:

为了比较SBRT治疗的HCC患者的人口统计,治疗和成本概况,与Y90.
评估SBRT和Y90队列之间的整体存活率 (OS) 和无进展存活率 (PFS).
分析SBRT与Y90对HCC治疗的成本效益.

主要方法:

在2018年1月至2020年1月期间接受SBRT或Y90治疗的HCC患者的回顾性评估.
使用基平方测试对人口统计和治疗数据进行比较.
使用卡普兰-梅尔曲线,日志等级测试和考克斯比例危险模型进行生存分析.
对一组患者的医疗保险成本分析.

主要成果:

在单变量和多变量分析中,SBRT和Y90组之间没有观察到OS或PFS的显著差异.
SBRT患者呈现出更先进的疾病,包括更高的AJCC阶段,更大的瘤大小,以及更多之前的肝脏导向疗法.
与Y90 (41,360美元) 相比,SBRT (15,148美元) 的平均医疗保险成本明显低于Y90 (41,360美元).

结论:

SBRT和Y90是有效的HCC治疗方法,具有可比的生存结果.
Y90放射栓塞比SBRT要昂贵得多.
需要进行前性研究,以进一步评估这些对HCC的废除方式的比较有效性和成本效益.

更多相关视频

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

相关概念视频

Hazard Ratio

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...